Teil 2: Plenary Session & ITP und Covid-19
(0:00 – 0:19)
Einleitung Teil 2
(0:19 – 05:46)
Neue Therapie für chron. ITP: Efgartigimod, a human IgG1 Fc-fragment
Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
Broome C. et al. #3
(05:46 – 08:27)
Was sagen uns aktuelle Registerdaten (UK, NL)?
Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopenia: a Multi-Centre Review
Sefani S. et al. #2444
(08:27 – 11:38)
Risiko eines ITP-Relaps bzw. – Onsets nach Covid-19 Infektion und nach Covid-19 Impfung
Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-CoV-2 Infection and Vaccination
Auteri G. et al. #3761
(11:38 – 12:13)
Covid-19 Impfung bei Kindern und jungen Erwachsenen mit bestehender ITP
COVID-19 Vaccination in Children and Young Adults with Pre-Existing Immune Thrombocytopenia (ITP): Preliminary Data from the Platelet Disorder Support Association (PDSA) Patient Registry
MacWhirter – DiRaimo J. et al. #1138
(12:13 – 13:14)
Zusammenfassung Sars-CoV-2 Infektion und Impfung bei ITP